肺炎支原体大环内酯类抗生素全球耐药现状和耐药机制研究进展

Progress in global drug resistance patterns and drug resistance mechanisms of Mycoplasma pneumoniae

肺炎支原体已成为社区获得性肺炎的首要致病菌，每3～7年在世界范围内暴发流行一次，其引起的临床症状多样化。自2000年开始，肺炎支原体的大环内酯类抗生素耐药现象快速增长，席卷全球多个国家，在某些地区其耐药率甚至高达100%，给人类的健康带来了巨大威胁。本文将对肺炎支原体的全球耐药状况和耐药机制等方面进行综述。

Mycoplasma pneumoniae （M.pneumoniae） is one of the predominant pathogenic bacteria causing community acquired pneumonia. An epidemic of M. pneumoniae infection occurs every three to seven years worldwide. It can cause a variety of clinical symptoms. Since 2000, macrolide-resistant M. pneumoniae strains have become increasingly common in many countries around the world and the drug resistance rate has reached as high as 100% in some area, which has posed a great threat to human health. This paper will review the status and mechanism of drug resistance in M. pneumoniae.